ストックスクリーナーアプリを入手
5.66
2.95%
0.1426
前日終値:
$5.5174
開ける：
$5.7
24時間の取引高:
2,304
Relative Volume:
0.08
時価総額：
$8.46M
収益：
-
当期純損益:
$-16.49M
株価収益率:
-0.191
EPS:
-29.6295
ネットキャッシュフロー:
$-15.24M
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
+12.03%
6か月 パフォーマンス:
+82.64%
1年 パフォーマンス:
-9.34%
1日の値動き範囲:
$5.4774
$5.79
1週間の範囲:
$5.44
$6.1899
52週間の値動き範囲:
$1.90
$10.59
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
名前
Cns Pharmaceuticals Inc
セクター
電話
1-800-946-9185
住所
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.79 | 8.77M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
542.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.37 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.15 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.68 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 開始されました | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa
Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com
CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan
CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year - Bitget
CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus & Indivior to merge in $2.2 billion CNS pharma deal - Voice of Healthcare
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.070|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CNSP - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring a 37% Potential Upside in CNS Therapeutics - DirectorsTalk Interviews
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNSP Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline AdvancesBasic EPS Analysis - vinanet.vn
CNSP Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesEarnings Surprise Report - dars.gov.et
CNSP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Drug Developer Navigates Clinical MilestonesEPS Guidance Update - vinanet.vn
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Costs PersistShare Repurchase Impact - DonanımHaber
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
CNS Pharmaceuticals Surges 18% as Momentum Builds (CNSP)Sweep Order Flow - dars.gov.et
CNS Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Stage Pressures - dars.gov.et
Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Enterprise value to EBIT forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals (CNSP) Dips 4% as Shares Approach Key Support LevelTPO Profile - dars.gov.et
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to sales forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Cns Pharmaceuticals Inc (CNSP) 財務データ
収益
当期純利益
現金流量
EPS
Cns Pharmaceuticals Inc (CNSP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Charles Faith L. | Director |
May 18 '26 |
Buy |
4.79 |
7,100 |
34,002 |
7,100 |
2.38%
大文字化:
|
ボリューム (24 時間):